International Journal of Clinical Psychiatry

International Journal of Psychiatry publishes original research articles on psychiatry. The journal aims to provide a communication platform for psychiatrists and doctors working on psychiatry discuss issues on the subject. Also the journal provides related solutions for difficulties they encounter in their research and work.


Lone G.M. Jorgensen

Editorial Board Member of International Journal of Clinical Psychiatry

Ms, Psychiatri Center Copenhagen, Denmark

Research Areas

Biochemistry, Psychiatry

Publications: Conferences/Workshops/Symposiums/Journals/Books

[1]  Jørgensen,L, Ranek,L. Systemisk lupus erythematosus klinisk debuterende som hepatitis. Ugeskrift for Læger 1983; 145: 578-9.
[2]  Jørgensen,L, Thomsen,P, Poulsen,HE. Disulfiram prevents acetaminophen hepatotoxicity in rats. Pharmacology & Toxicolo¬gy 1988; 62: 267-1.
[3]  Poulsen HE, Jørgensen L, Thomsen P. Prevention of acetaminophen hepatotoxicity by disulfiram. Pharmacol Ther 1987; 33: 83.
[4]  Poulsen,HE, Ranek,L, Jørgensen,L. The influence of disulfiram on acetaminophen metabolism in man. Xenobiotica 1991; 21: 243-9.
[5]  Jørgensen,L, Hansen,A Tybjærg, Thomsen,F. Metastatisk kalcifikation i lunger og ventrikel påvist ved knoglescintigrafi. Ugeskrift for Læger 1985; 147: 3902-3.
[6]  Munkner,T, Jørgensen,L. Cellular uptake of 131I-Meta-iodobenzylguanidine-I. J Pharm Clin 1: 13-8, 1985.
[7]  Munkner,T Jørgensen,L. Cellular uptake of 131I-Meta-iodobenzylguanidine-II (pp.526-32). In: Schmidt,HAE, Ell,PJ, Britton,KE (Eds.), Nuklearmedizin, Stuttgart-New York, FK Schattauer Verlag, 1986.
[8]  Mogensen PH, Jørgensen L, Boas J, Dam M, Vesterager A, Flesch G, Jensen PK. Effects of dextropropoxyphene on the steadystate kinetics of oxcarbazepine and its metabolites. Acta Neurologica Scandinavia 1992; 85: 14-7.
[9]  Ulla Finne, Lone Jørgensen, Henrik Ærenlund Jensen. Kalium og kostproblemer. Scandinavian Journal of Nutrition/Næringsforskning 1993; 37: 28-9 +34.
[10]  Jørgensen,L, Hansen,HH, Cooper,EH. Neuron Specific Enolase, Carcinoembryonic antigen and Lactate Dehydrogenase as indicators of disease activity in Small Cell Lung Cancer. European Journal of Cancer & Clinical Oncology 1989; 25: 123-8.
[11]  Jørgensen,L, Østerlind,K, Hansen,HH, Cooper,EH. The prognostic influence of neuron specific enolase in small cell lung cancer. British Journal of Cancer 1988; 58: 805-7.
[12]  Jørgensen, LGM, Hirsch, FR, Skov, BG, Østerlind, K, Cooper EH, Larsson LI. Occurence of Neuron Specific Enolase in Tumour Tissue and Serum in Small CellLung Cancer. British Journal of Cancer 1991; 63: 151-3.
[13]  Jørgensen LGM, Østerlind K, Hansen HH, Cooper EH. Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). British Journal of Cancer 1992; 66: 594-8.
[14]  Jørgensen LGM, Østerlind K, Hansen HH, Cooper EH. Neuron Specific Enolase (NSE) in progressive small cell lung cancer (SCLC). British Journal of Cancer 1994; 70:759-61.
[15]  Jørgensen LGM, Østerlind K, Genollá J, Gomm SA, Hernández JH, Johnson PWM, Løber J, Splinter TAW, Szturmowicz M. Serum neuron specific enolase (S-NSE) and the prognosis in small cell lung cancer (SCLC): A combined multivariable analysis on data from nine centres. Br J Cancer 1996; 74: 463-7.
[16]  Jørgensen LGM, Løber J, Carlsen NLT, Momsen G, Hirsch FR. Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. Clin Chim Acta 1996; 249: 77-91.
[17]  Jørgensen LGM, Prentø P, Jensen G. Neuron specific enolase (NSE) and the neuroendocrine and cytogenetic changes of small cell lung cancer (SCLC) cell lines during chemotherapy. J Tumor Marker Oncol 1996; 11 (3): 11-22.
[18]  Jørgensen LGM, Østerlind K, Gomm SA, Hernández JH, Johnson PWM, Løber J, Splinter TAW, Szturmowicz M. Tumour marker aided discrimination between disease stages in small cell lung cancer (SCLC). J Tumor Marker Oncol 1996; 11 (4): 7-14.
[19]  Jørgensen LGM, Böttcher SG, Christensen ES, Lundbye-Christensen S, Winkel P. Monitoring small cell lung cancer (SCLC) by serum neuron specific enolase (S-NSE) analyses using dynamic linear models. J Tumor Marker Oncol 1996; 11 (4): 15-21.
[20]  Prentø P, Jørgensen LGM. Applicability of direct or coupled enolase kinetic assays in clinical biochemistry. J Tumor Marker Oncol 1996; 11 (4): 29-34.
[21]  Momsen G, Jørgensen LGM. A multivariate control system for quality control of immunofluorometric assay for serum neuron specific enolase (S-NSE). J Tumor Marker Oncol 1996; 11 (4): 35-48.
[22]  Nielsen AL, Andersen EM, Jørgensen LGM, Jensen HÆ. Oxygen and 2,3 bisphosphoglycerate (2,3-BPG) during haemodialysis. Sicli 1998; 58 (6): 459-467.
[23]  Jørgensen LGM. Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation. Lægeforeningens Forlag, 1998 (disputats).
[24]  Jørgensen LGM. Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation. Danish Medical Bulletin, 1999; 46(1): 1-12.
[25]  Jørgensen LGM. Neuron specific enolase in small cell lung cancer. Clinical and biochemical evaluation, autoreferat af disputats. Ugeskrift for Læger, 1999; 161(2): 175.
[26]  Stahl M, Jørgensen LGM, Hyltoft Petersen P, Brandslund I, de Fine Olivarius N, Borch-Johnsen K. Optimization of preanalytical conditions and analysis of plasma glucose. The impact of the new WHO and ADA recommendations on the diagnosis of diabetes mellitus I. SICLI 2001; 61: 169-80.
[27]  Jørgensen LGM, Stahl M, Brandslund I, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. The plasma glucose reference interval in a low-risk population. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus II. SICLI 2001; 61: 181-90.
[28]  Hyltoft Petersen P, Brandslund I, Jørgensen LGM, Stahl M, de Fine Olivarius N, Borch-Johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glucose as basis for analytical quality specifications for the diagnosis ofdiabetes. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus diabetes III. SICLI 2001; 61: 191-204.
[29]  Jørgensen LGM. Neuron specific enolase (NSE) as prognostic factor in small cell lung cancer. J Tumor Marker Oncol 2001; 16: 9-12.
[30]  Jørgensen LGM, Brandslund I. Evaluation of tumour markers and clinical needs. J Tumor Marker Oncology 2001; 16: 13-16
[31]  Borggaard B, Jørgensen LGM. Cancer related genes. J Tumor Marker Oncol 2001; 16: 79-84.
[32]  Jørgensen, LGM, Brandslund I, Stahl M, Hyltoft Petersen P, Iversen S, Klitgaard N, de Fine Olivarius N. Upper reference limit, analytical quality specifications and clinical use of haemoglobin A1C. Scand J Clin Lab Invest 2002; 62: 609-22.
[33]  Stahl M, Brandslund I, Jørgensen LGM, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. Can capillary full blood glucose and venous plasma glucose measurements be used interchangeably? Diagnosis and control of type 2 Diabetes Mellitus 5. Scand J Clin Lab Invest 2002; 62 (2), 159-66.
[34]  Hyltoft Petersen P, Fraser CG, Jørgensen LGM, Brandslund I, Stahl M, Gowans EMS, Libeer J-C, Ricós C. Combination of analytical quality goals based on biological within-and between-subject variation. Ann Clin Biochem 2002; 39; 543-50
[35]  Jørgensen LGM, Schytte T, Brandslund I, Stahl M, Hyltoft Petersen P, Andersen B. The fasting and post glucose load reference limit of peripheral venous plasma glucose in pregnant women Clin Chem Lab Med 2003; 41(2): 187-99.
[36]  Jørgensen LGM, Brandslund I, Hyltoft Petersen P, de fine Olivarius, N Stahl M. The effect of the new ADA & WHO guidelines on the number of diagnosed diabetes mellitus cases. Clin Chem Lab Med; 2003: 41 (9): 1246-50
[37]  Hyltoft Petersen P, Jørgensen LGM, Jensen E, Kynde K, Brandslund I, Sandberg S, Stahl M. Er GUM skadelig?-eller blot overflødig. Klinisk Kemi i Norden 2003; 15(2): 27-31. Også som netversion på professor Westgards hjemmeside: http://www/westgard.com/guest24.htm.
[38]  Per Hyltoft Petersen, Lone GM Jørgensen, Esther Jensen, Karin Kynde, Ivan Brandslund, Sverre Sandberg, Marta Stahl. Er GUM relevant? Klinisk Biokemi I Norden 2003; 4: 31-36
[39]  Marta Stahl, Ivan Brandslund, Lone GM Jørgensen. Teknisk note. Kan bedside apparater til måling af glucose i plasmafase af fuldblod anvendes til diagnostik? ? Klinisk Biokemi I Norden 2003; 4: 41.
[40]  De fine Olivarius N, Jørgensen LGM, Brandslund I. Kan Hæmoglobin A1c anvendes til screening for type 2 diabetes? InfoMed nr. 4, 2003
[41]  Jørgensen LGM, Stahl M, Brandslund I, Hyltoft.Petersen P. Blodsukkermåling. InfoMed årgang 14: nr 24, oktober 2003
[42]  Per E Jørgensen, Jonna S Madsen, Lone GM Jørgensen, Torben B Larsen, Jørgen Hilden, Erik Magid. Lavt evidensniveau bag anbefalinger om diagnostisk anvendelse af klinisk biokemiske undersøgelser i Klaringsrapporterne 1996-2001. Ugeskr Læger 2004; 166: 1667-70
[43]  Erik Magid, Per E. Jørgensen, Lone G.M.Jørgensen, Jonna Skov Madsen, Torben B. Larsen & Jørgen Hilden-Dansk Selskab for Klinisk Biokemis arbejdsgruppe til fremme af evidensbaseret anvendelse af klinisk biokemi. Diagnostik: nye metodologiske initiativer Ugeskr Læger 2004; 166: 1664-66
[44]  Hyltoft Petersen P, Blaabjerg O, Andersen M, Jørgensen LGM, Schousboe K, Jensen E. Graphical interpretation of confidence curves in rankit plots. Clin Chem Lab Med 2004; 42 (7): 715-724
[45]  Lone G.M. Jørgensen, Ivan Brandslund, Per Hyltoft Petersen. Should we maintain the 95 percent reference intervals in the wellness testing era? A concept paper. Clin Chem Lab Med 2004; 42 (7): 747-751.
[46]  Lone G.M. Jørgensen, Ivan Brandslund, Per Hyltoft Petersen, Marta Stahl, Niels de Fine Olivarius. Creation of a low risk reference group and reference interval of fasting venous plasma glucose. Clin Chem Lab Med 2004; 42 (7): 817-823.
[47]  Tine Schytte, Lone GM Jørgensen, Ivan Brandslund, Per Hyltoft Petersen, Bent Andersen. Neonatal and maternal clinical outcome in cases screened positive versus negative for gestational diabetes. CCLM 2004; 42: 1036-42.
[48]  Jørgensen PE, Magid E, Madsen JS, Hilden J, Jørgensen LGM, Larsen TB. Diagnostik: nye metodologiske initiativer-2. Klin Kem i Norden 2004
[49]  Lone G.M. Jørgensen, Per Hyltoft Petersen, Ivan Brandslund. Risk of diabetes mellitus based on ADA criteria as gold standard. Int J Risk Assessment and Management vol.00. Nos0/0.0000 Int J Risk Assessment and Management 2005; 5(2/3/4): 358-73.
[50]  Lone G.M. Jørgensen, Lisbeth Fredholm, Per Hyltoft Petersen, Henrik Hey, Pia Munkholm, Ivan Brandslund.. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD). Clin Chem Lab Med 2005; 43(4):403-11
[51]  Jørgensen, LGM, Brandslund I, Hey H, Hyltoft Petersen P. Signal-støjforhold bestemmer kritisk differens for prognostisk indeks af daglig klinisk monitorering af Crohn´s sygdom. Medlems Nut. Dansk Selskab for Klinisk Biokemi. 1/2005: 5-7
[52]  Per Hyltoft Petersen, Lone G M Jørgensen, Ivan Brandslund, Niels de Fine Olivarius, Marta Stahl. Consequences of bias and imprecision of glucose and HbA1c measurements for the diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2005; 65 (Suppl 240) 51-60.
[53]  Martin Eivindson1,2, Henning Grønbæk2, Jens Nederby Nielsen4, Jan Frystyk3, Allan Flyvbjerg3, Lone Jørgensen4, Henrik Hey1,5 and the DANUT-group6 Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with ω-3 orω-6 fatty acids and corticosteroids. Scand J Gastroenterol. 2005;40(10):1214-21.
[54]  Aneta Aleksandra Nielsen1, Lone GM Jørgensen1, Jens Nederby Nielsen1, Martin Eivindson1, 2, Ida Vind3, Pia Munkholm4, David Hougaard5, Henning Grønbæk2, Søren Jensen6, Ivan Brandslund1, 8, Henrik Hey7, 8 Cytokines profiles during treatment with omega-3/6 fatty acids in patients with active Crohn's Disease. Aliment Pharmacol Ther. 2005;22(11-12):1121-1128.
[55]  Lone G.M. Jørgensen, Per Hyltoft Petersen, Lene Heickendorff, Holger John Møller, Jørn Hendel, Cramer Christensen, Anita Schmitz, Birgitte Reinholdt, Erik D Lund, Niels J Christensen, Erik Kjærsgaard Hansen, Jens Hastrup, Hanne Skjødt, Ebbe Wendel Eriksen, Ivan Brandslund. Glucemic control in diabetes in three Danish counties Clin Chem Lab Med 2005; 43 (12): 1366-1372.
[56]  Natalia Iglesias1, Per Hyltoft Petersen2, Lone G.M. Jørgensen3, Ivan Brandslund. Letter to the editor. Comments on HbA1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose. Annals of Clinical Biochemistry in press
[57]  Lone G.M. Jørgensen. Has ideology something to do with evidence or assumption? BMJ Rapid response, 10 October 2005
[58]  N. de Fine Olivarius and L.G.M. Jørgensen Near-patient blood glucose measurements should only be used alone in the diagnosis of diabetes in cases of high glucose concentrations. Diabetic Medicine 2006;23:1042-1044.
[59]  Jørgensen LGM et al. Clinical use of cellular anticoagulants in secundary prevention of cerebrovascular events (Final edition ready before Christmas)
[60]  Lone G.M. Jørgensen. Where does the evidence come from? Clim Chem Lab Med 2006;44(1):1-2.
[61]  Lone G.M. Jørgensen, Ivan Brandslund, Per Hyltoft Petersen , Cramer Christensen, Ebbe Wendel Eriksen. Elleven years' glucated haemoglobin as indicator of incidence, prevalence and treatment efficacy of diabetes mellitus in general practice and hospitals. Clin Chem Lab Med 2006; 44(1):92-8.
[62]  Niels de Fine Olivarius, Anne H. Andreasen, Else Vestbo, Niels-Henrik Holstein-Rathlou, Lone G. M. Jørgensen, Carl Erik Mogensen. Urinary creatinine concentration is inversely related to glycaemic control and the presence of some diabetic complications in patients with newly diagnosed type 2 diabetes" Journal of Diabetes and Its Complications 2006;20: 45-50.
[63]  Lone G.M. Jørgensen. Sensitivity and significance of disease outcome measures in inflammatory bowel disease Quality in the Spotlight Conference, Antwerpen, Belgium Accred Qual Assue 2006;11: 297-302.
[64]  Lone G.M. Jørgensen, Henrik Hey, Ivan Brandslund, Martin Eivindson, Ida Vind, Henning Grønbæk, Søren Jensen, Per Hyltoft Petersen. How accurate are wellness scores in Crohn´s disease. Accred Qual Assue 2006;11: 278-83.
[65]  Lone G.M. Jørgensen, Internationalisation of scientific reports on disease scores. Accred Qual Assue 2006;11: 313-14
[66]  Lone G.M. Jørgensen, Per Hyltoft Petersen, Ivan Brandslund. Clinical outcome estimates based on treatment target limits of laboratory tests: Proposal for a plot visualising effects and differences of medical target setting exemplified by glycemic control in diabetes. In press 2006;44:327-32.
[67]  Hyltoft Petersen P, Sandberg S, Iglesias N, Brandslund I, Jørgensen LGM. Likely hood-ratio and odds applied to monitoring of patients as a supplement to reference change value (RCV) Clin Chem Lab Med 2008; 46(2):157-164.
[68]  Madsen JS, Nybo M, Magid E, Hilden J, Hornung N, Larsen TB, Jørgensen L, Jørgensen PE. More studies on outcome of diagnostic biochemical tests are needed. Clin Biochem 2008